Affinage

SCARA5

Scavenger receptor class A member 5 · UniProt Q6ZMJ2

Length
495 aa
Mass
54.0 kDa
Annotated
2026-06-10
52 papers in source corpus 19 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SCARA5 is a type II transmembrane homotrimeric class A scavenger receptor that functions principally as an endocytic receptor mediating iron homeostasis, innate immunity, and tumor suppression (PMID:16407294). Its founding role is as a ferritin (L-ferritin) receptor that binds serum ferritin at the cell surface and internalizes it to deliver iron independently of the transferrin/TfR1 pathway (PMID:19154717), an activity later shown to support ferritin transcytosis across the blood-retinal barrier on endothelial cells (PMID:25259650). Beyond ferritin, SCARA5 acts as an adhesive and endocytic receptor for von Willebrand factor and the VWF-FVIII complex, internalizing them into early endosomes in podocytes and splenic littoral endothelium (PMID:31126000), and it clears the inflammatory mediator HMGB1 into lysosomes to dampen inflammatory signaling (PMID:27647835). As a tumor suppressor, SCARA5 physically associates with FAK and restrains the FAK-Src-p130Cas cascade, limiting MMP9 activation, invasion, and metastasis (PMID:20038795). SCARA5 also drives ferroptosis: it binds ferritin light chain (FTL) and promotes autophagic ferritin degradation to raise intracellular Fe2+ and lipid ROS (PMID:36513999, PMID:39954713), and it interacts with GPX4 to reduce its expression, sensitizing cells to ferroptosis (PMID:41270385). SCARA5 transcription is directly repressed by Snail1 binding to promoter E-boxes during TGF-β1-induced EMT, in concert with DNMT1 (PMID:24061576), and is suppressed downstream of β-catenin/TCF4 signaling (PMID:30249289).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2006 High

    Established SCARA5 as a structurally distinct class A scavenger receptor, defining its membrane topology, oligomeric state, and ligand selectivity to separate it from SR-A/MARCO.

    Evidence cDNA cloning and CHO cell transfection with plasma membrane localization, bacterial binding, and modified-LDL uptake assays

    PMID:16407294

    Open questions at the time
    • Does not identify physiological endogenous ligands beyond bacteria
    • SRCR-domain ligand-binding determinants not mapped at residue level
  2. 2009 High

    Resolved how cells acquire iron independently of transferrin by identifying SCARA5 as a cell-surface ferritin receptor mediating ferritin endocytosis and iron delivery.

    Evidence TfR1-/- chimeric embryo model with fluorescence-tagged kidney capsule cells plus cell-based ferritin binding/endocytosis and in vivo iron delivery assays

    PMID:19154717

    Open questions at the time
    • Endocytic adaptor and trafficking machinery not defined
    • Quantitative contribution to systemic iron balance not established
  3. 2009 High

    Defined a tumor-suppressive mechanism by showing SCARA5 physically binds FAK and suppresses the FAK-Src-p130Cas invasion-promoting cascade.

    Evidence Reciprocal Co-IP for FAK association, RNAi/overexpression with in vitro invasion and in vivo metastasis assays, phosphorylation western blots in HCC

    PMID:20038795

    Open questions at the time
    • How an endocytic surface receptor engages cytoplasmic FAK is structurally unclear
    • Cytoplasmic-tail residues mediating FAK binding not mapped
  4. 2013 High

    Identified upstream transcriptional silencing of SCARA5, showing Snail1 directly represses its promoter during EMT in cooperation with DNMT1.

    Evidence ChIP for Snail1 binding to promoter E-boxes, Snail1 gain/loss-of-function, Snail1-DNMT1 Co-IP in a TGF-β1-induced EMT A549 model

    PMID:24061576

    Open questions at the time
    • DNA methylation-independent mechanism of DNMT1 action not fully defined
    • Generality across non-lung tumor types not tested
  5. 2014 Medium

    Extended ferritin-receptor function to a barrier-transport context by showing endothelial SCARA5 mediates L-ferritin transcytosis across the blood-retinal barrier.

    Evidence In vivo intravenous ferritin injection with Scara5/ferritin colocalization immunohistochemistry and photoreceptor degeneration model

    PMID:25259650

    Open questions at the time
    • Transcytosis inferred from colocalization rather than directional flux measurement
    • Single lab, no genetic loss-of-function for barrier transport
  6. 2016 Medium

    Broadened the receptor repertoire to innate immune mediator clearance, showing the SCARA5 ortholog endocytoses HMGB1 in a redox-dependent manner to lysosomes and dampens inflammation.

    Evidence Reciprocal Co-IP with A/B/T box domain mapping, redox-dependency and lysosomal trafficking assays in fish cell models with cytokine readouts

    PMID:27647835

    Open questions at the time
    • Demonstrated in fish ortholog, not human SCARA5
    • Single lab
  7. 2016 Medium

    Suggested context-dependent pro-proliferative signaling by placing SCARA5 as a positive regulator of PDGF-driven proliferation and migration in vascular smooth muscle.

    Evidence siRNA knockdown in HASMCs with proliferation/migration assays and PDGFRβ/AKT/ERK1/2 phosphorylation western blots

    PMID:27035566

    Open questions at the time
    • No direct binding to PDGF pathway components shown
    • Apparent positive signaling role conflicts with tumor-suppressive FAK data; reconciliation unaddressed
  8. 2017 Medium

    Implicated SCARA5 in mesenchymal cell fate by showing it promotes adipocyte lineage commitment via FAK/ERK signaling under glucocorticoid control.

    Evidence RNAi/overexpression in A33 and C3H10T1/2 cells with adipogenesis assays, FAK/ERK western blots, and a promoter-GRE reporter

    PMID:29093466

    Open questions at the time
    • Direct receptor ligand driving differentiation not identified
    • Single lab
  9. 2018 Medium

    Connected SCARA5 transcriptional suppression to canonical β-catenin signaling via the SPAG5-β-catenin/TCF4 axis in HCC.

    Evidence SPAG5 overexpression/knockdown with β-catenin ubiquitination assays, SCARA5 rescue, and xenografts

    PMID:30249289

    Open questions at the time
    • No direct TCF4 binding to SCARA5 promoter demonstrated
    • Single lab
  10. 2019 High

    Established SCARA5 as a receptor for von Willebrand factor and the VWF-FVIII complex, defining a hemostatic clearance/adhesion function in podocytes and splenic littoral endothelium.

    Evidence Solid-phase binding with recombinant SCARA5, HEK293T endocytosis into early endosomes, tissue colocalization, and SCARA5-deficient mouse VWF half-life

    PMID:31126000

    Open questions at the time
    • In vivo effect on VWF half-life was modest, leaving physiological significance unclear
    • Binding domain on SCARA5 not mapped
  11. 2021 Medium

    Identified a cell-cycle arrest mechanism downstream of SCARA5 via HSPA5 upregulation and FOXM1 suppression causing G2/M arrest in NSCLC.

    Evidence RNA-seq, luciferase reporter, western blot, flow cytometry, and xenograft

    PMID:34150631

    Open questions at the time
    • How a scavenger receptor controls HSPA5 transcription is unresolved
    • Direct molecular link between SCARA5 and HSPA5 not shown
  12. 2022 Medium

    Initiated the ferroptosis model by showing SCARA5 binds FTL and raises intracellular Fe2+ to induce ferroptosis in ESCC.

    Evidence Co-IP for SCARA5-FTL, flow cytometry for ROS/Fe2+, TEM for mitochondrial morphology, ferroptosis markers, and xenograft

    PMID:36513999

    Open questions at the time
    • Mechanism linking FTL binding to Fe2+ release not defined here
    • Single lab
  13. 2024 Medium

    Revealed SCARA5 as a cell-surface autoantigen in multiple sclerosis, targeted by a CSF IgM that drives complement activation and T-cell infiltration.

    Evidence IP-mass spectrometry antigen identification, recombinant IgM, complement activation assay, and intrathecal injection in EAE

    PMID:38123517

    Open questions at the time
    • Frequency and pathogenic role of anti-SCARA5 IgM across MS patients not established
    • Mechanism by which the antibody alters SCARA5 receptor function unknown
  14. 2025 Medium

    Mechanistically unified SCARA5's pro-ferroptotic activity, showing it promotes autophagic ferritin degradation to elevate Fe2+/lipid ROS and that loss confers sorafenib resistance.

    Evidence Erastin/RSL3 viability, ROS/lipid ROS/MDA/Fe2+ measurements, autophagy flux assays, and SCARA5-knockout MEFs/HCC cells

    PMID:39954713

    Open questions at the time
    • How SCARA5 triggers ferritinophagy molecularly not resolved
    • Single lab
  15. 2025 Medium

    Added a GPX4 regulatory arm to the ferroptosis mechanism, showing SCARA5 interacts with and downregulates GPX4 and that its restoration alleviates liver fibrosis.

    Evidence Co-IP and molecular docking for SCARA5-GPX4, redox/iron measurements, DNMT1-methylation analysis, and HSC-specific SCARA5 knock-in mouse

    PMID:41270385

    Open questions at the time
    • Mechanism by which SCARA5 lowers GPX4 (transcriptional vs degradation) not defined
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single surface scavenger receptor reconciles opposing roles—pro-proliferative PDGF signaling versus tumor-suppressive FAK inhibition and ferroptosis induction—and which cytoplasmic-tail determinants route it between endocytosis, signaling, and ferritinophagy remains unresolved.
  • No structural model of the SCARA5 cytoplasmic tail engaging FAK, FTL, or GPX4
  • Context-dependent pro- vs anti-tumor activities not mechanistically reconciled
  • Direct adaptor machinery for ferritin/VWF/HMGB1 endocytosis undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0038024 cargo receptor activity 4 GO:0098631 cell adhesion mediator activity 2 GO:0098772 molecular function regulator activity 2
Localization
GO:0005886 plasma membrane 2 GO:0005768 endosome 1
Pathway
R-HSA-5357801 Programmed Cell Death 3 R-HSA-168256 Immune System 2 R-HSA-5653656 Vesicle-mediated transport 2 R-HSA-109582 Hemostasis 1
Partners
FAKFTLGPX4HMGB1VWF

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2009 SCARA5 is a ferritin receptor that binds serum ferritin at the cell surface and mediates its endocytosis, resulting in intracellular iron delivery independent of the transferrin/TfR1 pathway. This was demonstrated in kidney capsule cells during organogenesis. Chimeric embryo model (TfR1-/- fluorescence-tagged cells), cell-based ferritin binding and endocytosis assays, in vivo iron delivery assay Developmental cell High 19154717
2006 SCARA5 is a type II transmembrane protein that assembles as a homotrimer at the plasma membrane. It contains C-terminal intracellular, transmembrane, extracellular spacer, collagenous, and N-terminal scavenger receptor cysteine-rich (SRCR) domains. SCARA5-transfected cells bound E. coli and S. aureus in a polyanionic-inhibitable manner but could not endocytose acetylated or oxidized LDL, distinguishing it from SR-A1/II and MARCO. cDNA cloning, CHO cell transfection, plasma membrane localization assay, bacterial binding assay, modified LDL uptake assay The Journal of biological chemistry High 16407294
2009 SCARA5 physically associates with focal adhesion kinase (FAK) and inhibits the tyrosine phosphorylation cascade of the FAK-Src-p130Cas signaling pathway. Silencing SCARA5 increased phosphorylation of FAK, Src, and p130Cas, and activated MMP9, promoting HCC cell invasion and metastasis. Co-immunoprecipitation (physical association with FAK), RNAi knockdown, overexpression, in vitro invasion/colony formation assays, in vivo tumorigenicity and lung metastasis assays, phosphorylation analysis by western blot The Journal of clinical investigation High 20038795
2013 Snail1 directly represses SCARA5 transcription by binding to E-box elements in the SCARA5 promoter, and this repression is required for TGF-β1-induced EMT-associated cell migration in A549 lung carcinoma cells. DNA methyltransferase 1 (DNMT1) was found to be physically associated with Snail1 to silence SCARA5 expression via a DNA methylation-independent mechanism. Chromatin immunoprecipitation (ChIP) assay for Snail1 binding to SCARA5 promoter E-boxes, gain- and loss-of-function experiments for Snail1, Co-IP for Snail1-DNMT1 association, TGF-β1-induced EMT model, cell migration assay Oncogenesis High 24061576
2014 SCARA5 (Scara5) expressed on retinal endothelial cells acts as a receptor for L-ferritin, mediating ferritin transcytosis across the blood-retinal barrier. Intravenously injected ferritin crossed the blood-retinal barrier by binding to Scara5 on endothelial cells. In vivo intravenous ferritin injection, immunohistochemistry for Scara5/ferritin colocalization in mouse and human retina, murine photoreceptor degeneration model PloS one Medium 25259650
2016 SCARA5 acts as an endocytic receptor for HMGB1 in fish (pufferfish/zebrafish) models. SCARA5 associates with HMGB1 through the A and B boxes of HMGB1, depending on the redox state of cysteine residues (T box inhibits the association). SCARA5 mediates endocytosis of HMGB1 into lysosomes and negatively regulates HMGB1-mediated inflammatory signaling by clearing the HMGB1 mediator. Co-immunoprecipitation for SCARA5-HMGB1 interaction, domain mapping (A/B/T box), redox-state dependency assay, endocytosis/lysosome trafficking assay, overexpression/knockdown in fish cell models, cytokine expression assay Journal of immunology Medium 27647835
2019 Human SCARA5 is an adhesive and endocytic receptor for von Willebrand factor (VWF) and the VWF-FVIII complex, binding in a dose- and calcium-dependent manner. SCARA5-expressing HEK293T cells internalized VWF and VWF-FVIII into early endosomes. In human tissues, SCARA5 is expressed by kidney podocytes and splenic littoral endothelial cells lining the red pulp, where it colocalizes with VWF. SCARA5 deficiency had a modest influence on VWF half-life in vivo. Solid-phase binding assay (recombinant SCARA5 protein), HEK293T cell-based endocytosis assay, immunohistochemistry for tissue localization and VWF colocalization, SCARA5-deficient murine model for VWF half-life Journal of thrombosis and haemostasis : JTH High 31126000
2017 SCARA5 plays a role in adipocyte lineage commitment and differentiation of mesenchymal stem cells. RNAi-mediated knockdown of SCARA5 inhibited adipogenic potential of preadipocyte A33 cells, while overexpression enhanced adipocyte differentiation in C3H10T1/2 pluripotent stem cells. The FAK and ERK signaling pathways were found to be associated with SCARA5-mediated adipocyte commitment. Glucocorticoids induced SCARA5 expression through glucocorticoid response elements (GRE) in the SCARA5 promoter. Gain- and loss-of-function (RNAi, overexpression) in A33 and C3H10T1/2 cells, adipogenesis assays, western blot for FAK/ERK phosphorylation, promoter-GRE reporter assay Scientific reports Medium 29093466
2016 SCARA5 knockdown in vascular smooth muscle cells (HASMCs) inhibited PDGF-BB-induced proliferation and migration by suppressing phosphorylation of PDGFRβ, AKT, and ERK1/2, placing SCARA5 as a positive regulator within the PDGF signaling pathway in VSMCs. siRNA knockdown of SCARA5 in HASMCs, MTT proliferation assay, migration assay, western blot for PDGFR-β/AKT/ERK1/2 phosphorylation Molecular medicine reports Medium 27035566
2022 SCARA5 binds directly to ferritin light chain (FTL) and promotes intracellular Fe2+ accumulation, leading to ferroptosis in esophageal squamous cell carcinoma (ESCC) cells. Co-immunoprecipitation confirmed the SCARA5-FTL interaction; overexpression of SCARA5 induced mitochondrial morphology changes, ROS accumulation, and increased Fe2+ consistent with ferroptosis. Co-immunoprecipitation (SCARA5-FTL interaction), flow cytometry (ROS, Fe2+), transmission electron microscopy (mitochondrial morphology), western blot (ferroptosis markers), xenograft model BMC cancer Medium 36513999
2018 SPAG5 promotes HCC progression by downregulating SCARA5 expression through the β-catenin/TCF4 signaling pathway, specifically by modulating β-catenin degradation (reduced ubiquitination of β-catenin), which in turn suppresses SCARA5 transcription. SPAG5 overexpression and shRNA knockdown in HCC cells, western blot and RT-PCR for β-catenin and SCARA5, rescue experiments with SCARA5, in vivo xenograft model Journal of experimental & clinical cancer research : CR Medium 30249289
2016 Rock2 (ROCK2 kinase) decreases SCARA5 expression in renal cell carcinoma via the β-catenin/TCF4 pathway. Rock2 knockdown increased SCARA5 expression and suppressed RCC cell proliferation, establishing a Rock2-β-catenin/TCF4-SCARA5 regulatory axis. Rock2 knockdown by siRNA/shRNA, western blot and RT-PCR for SCARA5 and β-catenin pathway components, in vitro proliferation assay, in vivo xenograft Biochemical and biophysical research communications Low 27793664
2017 CSN5 (COP9 signalosome subunit 5 / E3 ubiquitin ligase) decreases β-catenin ubiquitination, leading to elevated β-catenin protein levels that suppress SCARA5 expression in HCC. CSN5 knockdown increased SCARA5 expression and inhibited HCC proliferation and metastasis in vitro and in vivo. CSN5 overexpression and lentiviral knockdown in HCC cells, western blot for β-catenin ubiquitination and SCARA5, RT-PCR, immunohistochemistry, in vivo xenograft Digestive diseases and sciences Low 29189991
2025 SCARA5 enhances intracellular availability of bioactive ferrous iron (Fe2+) by promoting autophagic degradation of ferritin (the major iron storage protein), thereby sensitizing HCC cells to ferroptosis induced by erastin and RSL3. SCARA5-deficient cells showed reduced ferroptosis sensitivity and contributed to sorafenib resistance. Cell viability assay (erastin/RSL3 treatment), ROS/lipid ROS/MDA/Fe2+ measurement, autophagy flux assay for ferritin degradation, SCARA5-knockout MEFs and HCC cells, sorafenib resistance assay Cellular signalling Medium 39954713
2025 SCARA5 physically interacts with GPX4 (glutathione peroxidase 4), negatively regulating its expression. Baicalein promotes SCARA5 expression (via inhibiting DNMT1-mediated methylation of the SCARA5 promoter), which through its negative effect on GPX4 promotes ferroptosis in hepatic stellate cells. HSC-specific knock-in of SCARA5 alleviated liver fibrosis in mice. Co-immunoprecipitation (SCARA5-GPX4 interaction), molecular docking, western blot for GPX4/SCARA5/DNMT1, Fe2+/MDA/ROS/GSH measurement, SCARA5 knock-in mouse model, Masson staining for fibrosis Phytomedicine Medium 41270385
2021 SCARA5 overexpression in NSCLC upregulates HSPA5, which inhibits FOXM1 expression, leading to G2/M cell cycle arrest. This pathway was identified by RNA sequencing and validated with luciferase-based gene reporter assay and western blot. RNA sequencing transcriptome profiling, luciferase reporter assay, western blot (HSPA5, FOXM1 expression), flow cytometry (G2/M cell cycle arrest), in vivo xenograft Frontiers in oncology Medium 34150631
2025 SCARA5 physically interacts with FTL (ferritin light chain) protein, and SCARA5 upregulation reduces FTL protein ubiquitination, thereby stabilizing FTL and promoting ferroptosis by inhibiting mitochondrial damage in colon cancer cells. Co-immunoprecipitation (SCARA5-FTL interaction), ubiquitination assay for FTL, si-FTL rescue experiment, cell viability assay, ferroptosis markers American journal of cancer research Low 40084377
2024 SCARA5 was identified as an autoantigen target of a CSF-derived IgM antibody in multiple sclerosis patients. The IgM antibody bound SCARA5 on the cell surface and mediated antigen-dependent complement activation. Intrathecal injection of a SCARA5 antibody increased T cell infiltration in an EAE model. Immunoprecipitation and mass spectrometry for antigen identification, recombinant monoclonal IgM antibody production, complement activation assay, intrathecal antibody injection in EAE mouse model Brain : a journal of neurology Medium 38123517
2025 FOXO1 transcription factor positively regulates SCARA5 expression in human endometrial stromal cells. Knockdown of FOXO1 decreased SCARA5 expression, and FOXO1 protein was identified as a direct target of miR-424 (via its 3'-UTR by luciferase assay). miR-424/miR-503 overexpression suppressed SCARA5 expression during decidualization. FOXO1 knockdown (RT-PCR for SCARA5 expression), luciferase reporter assay (miR-424 targeting FOXO1 3'-UTR), miRNA overexpression in HESCs, immunofluorescence Medical molecular morphology Low 40085209

Source papers

Stage 0 corpus · 52 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2009 Scara5 is a ferritin receptor mediating non-transferrin iron delivery. Developmental cell 286 19154717
2006 Identification and characterization of murine SCARA5, a novel class A scavenger receptor that is expressed by populations of epithelial cells. The Journal of biological chemistry 124 16407294
2009 Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. The Journal of clinical investigation 121 20038795
2013 Suppression of SCARA5 by Snail1 is essential for EMT-associated cell migration of A549 cells. Oncogenesis 76 24061576
2014 L-ferritin binding to scara5: a new iron traffic pathway potentially implicated in retinopathy. PloS one 54 25259650
2018 SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation. Journal of experimental & clinical cancer research : CR 49 30249289
2017 SCARA5 plays a critical role in the progression and metastasis of breast cancer by inactivating the ERK1/2, STAT3, and AKT signaling pathways. Molecular and cellular biochemistry 46 28497372
2018 Downregulation of SCARA5 may contribute to breast cancer via promoter hypermethylation. Gene 35 29908284
2016 Overexpression of SCARA5 inhibits tumor proliferation and invasion in osteosarcoma via suppression of the FAK signaling pathway. Molecular medicine reports 31 26847210
2017 SCARA5 plays a critical role in the commitment of mesenchymal stem cells to adipogenesis. Scientific reports 26 29093466
2022 SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with Ferritin light chain. BMC cancer 25 36513999
2016 Rock2 promotes RCC proliferation by decreasing SCARA5 expression through β-catenin/TCF4 signaling. Biochemical and biophysical research communications 25 27793664
2014 Identification of SCARA3, SCARA5 and MARCO of class A scavenger receptor-like family in Pseudosciaena crocea. Fish & shellfish immunology 24 25218683
2019 The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen. Journal of thrombosis and haemostasis : JTH 23 31126000
2016 Scavenger Receptor SCARA5 Acts as an HMGB1 Recognition Molecule Negatively Involved in HMGB1-Mediated Inflammation in Fish Models. Journal of immunology (Baltimore, Md. : 1950) 22 27647835
2017 CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination. Digestive diseases and sciences 21 29189991
2022 BMSC-derived exosomal lncRNA PTENP1 suppresses the malignant phenotypes of bladder cancer by upregulating SCARA5 expression. Cancer biology & therapy 20 35998226
2020 SCARA5 is a Novel Biomarker in Colorectal Cancer by Comprehensive Analysis. Clinical laboratory 19 32658413
2021 SCARA5 suppresses the proliferation and migration, and promotes the apoptosis of human retinoblastoma cells by inhibiting the PI3K/AKT pathway. Molecular medicine reports 18 33495818
2021 SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression. Journal of Cancer 16 33758617
2017 Methylation analysis of p16, SLIT2, SCARA5, and Runx3 genes in hepatocellular carcinoma. Medicine 16 29019900
2023 The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF-FVIII clearance in thrombosis and hemostasis. Journal of thrombosis and haemostasis : JTH 15 37085036
2018 Identification of three class A scavenger receptors from rainbow trout (Oncorhynchus mykiss): SCARA3, SCARA4, and SCARA5. Fish & shellfish immunology 15 29471060
2022 Carcinoma-associated fibroblasts release microRNA-331-3p containing extracellular vesicles to exacerbate the development of pancreatic cancer via the SCARA5-FAK axis. Cancer biology & therapy 14 35510828
2018 Identification of SCARA5 as a Potential Biomarker for Oral Squamous Cell Carcinoma using MALDI-TOF-MS Analysis. Proteomics. Clinical applications 14 29461673
2016 Knockdown of SCARA5 inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration through suppression of the PDGF signaling pathway. Molecular medicine reports 14 27035566
2021 The Novel Methylation Biomarker SCARA5 Sensitizes Cancer Cells to DNA Damage Chemotherapy Drugs in NSCLC. Frontiers in oncology 13 34150631
2023 SCARA5 in bone marrow stromal cell-derived exosomes inhibits colorectal cancer progression by inactivating the PI3K/Akt pathway. Genomics 12 37150230
2017 Correction: L-Ferritin Binding to Scara5: A New Iron Traffic Pathway Potentially Implicated in Retinopathy. PloS one 11 28640867
2024 Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5. Brain : a journal of neurology 10 38123517
2015 Scavenger receptor class A member 5 (SCARA5) and suprabasin (SBSN) are hub genes of coexpression network modules associated with peripheral vein graft patency. Journal of vascular surgery 10 25935274
2024 G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1. Cell death & disease 9 39488528
2022 Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma. Journal of immunology research 9 35755171
2018 The characterization and initial immune functional analysis of SCARA5 in turbot (Scophthalmus maximus L.). Fish & shellfish immunology 9 30006044
2024 Paeonol upregulates expression of tumor suppressors TNNC1 and SCARA5, exerting anti-tumor activity in non-small cell lung cancer cells. Naunyn-Schmiedeberg's archives of pharmacology 8 38265681
2023 SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways. Open medicine (Warsaw, Poland) 8 36785765
2020 Identification of SCARA5 Gene as a Potential Immune-Related Biomarker for Triple-Negative Breast Cancer by Integrated Analysis. DNA and cell biology 8 32816580
2023 SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and invasion of bladder cancer. Genomics 7 37315873
2022 Sequence and functional features of a novel scavenger receptor homolog, SCARA5 from Yellow drum (Nibea albiflora). Developmental and comparative immunology 7 35690228
2023 m6A-mediated upregulation of lncRNA RMRP boosts the progression of bladder cancer via epigenetically suppressing SCARA5. Epigenomics 6 37337726
2025 SCARA5 deficiency inhibits ferroptosis via regulating iron homeostasis and results in sorafenib resistance in hepatocellular carcinoma. Cellular signalling 5 39954713
2024 Selective Pyk2 inhibition enhances bone restoration through SCARA5-mediated bone marrow remodeling in ovariectomized mice. Cell communication and signaling : CCS 3 39578816
2025 Loss of miR-424 and miR-503 promotes decidualization of human endometrial stromal cells by increasing SCARA5 expression. Medical molecular morphology 2 40085209
2025 Baicalein facilitates hepatic stellate cell ferroptosis via the DNMT1/SCARA5/GPX4 axis. Phytomedicine : international journal of phytotherapy and phytopharmacology 2 41270385
2024 The Role of SCARA5 as a Potential Biomarker in Squamous Cell Carcinoma of the Lung. International journal of molecular sciences 2 39000462
2025 SCARA5 might be one potential marker for CC and promoted Ferroptosis by FTL. American journal of cancer research 1 40084377
2023 Methylated tumor suppressor gene SCARA5 inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma. Epigenomics 1 37554122
2026 The LincRNA8058-mediated chi-miR-342-5p/SCARA5 axis regulates milk fat metabolism in dairy goats. International journal of biological macromolecules 0 41539521
2026 TMT proteomics reveals that miR-425-5p promotes proliferation and metastasis of malignant melanoma by inhibiting SCARA5. Cancer cell international 0 41736072
2025 Retraction of: "SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways". Open medicine (Warsaw, Poland) 0 41141927
2025 SCARA5 Induces Ferroptosis to Inhibit the Proliferation and Migration of Skin Melanoma Cells and Regulates the GPX4/ACSL4 Signaling Pathway. Archivum immunologiae et therapiae experimentalis 0 41206901
2025 Advances in studying the role of SCARA5 in tumors. Biochemical and biophysical research communications 0 41429094

Missed literature

Know a paper Affinage missed for SCARA5? Flag it for the maintainers and the community.

No submissions yet.